Skip to main content
SpringerLink
Log in

Hepatotoxicity as a rare but serious side effect of Thalidomide

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802–1811 doi:10.1016/S0140-6736(04)16308-3

    Article  PubMed  CAS  Google Scholar 

  2. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436 doi:10.1200/JCO.2005.03.0221

    Article  PubMed  CAS  Google Scholar 

  3. Trojan A, Chasse E, Gay B, Pichert G, Taverna C (2003) Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Ann Oncol 14:501–502 doi:10.1093/annonc/mdg095

    Article  PubMed  CAS  Google Scholar 

  4. Hussain S, Browne R, Chen J, Parekh S (2007) Lenalidomide-induced severe hepatotoxicity. Blood 110:3814 doi:10.1182/blood-2007-06-097758

    Article  PubMed  CAS  Google Scholar 

  5. Hanje AJ, Shamp JL, Thomas FB, Meis GM (2006) Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26:1018–1022 doi:10.1592/phco.26.7.1018

    Article  PubMed  Google Scholar 

  6. Fowler R, Imrie K (2001) Thalidomide-associated hepatitis: a case report. Am J Hematol 66:300–302 doi:10.1002/ajh.1062

    Article  PubMed  CAS  Google Scholar 

  7. Teo SK, Sabourin PJ, O’Brien K, Kook KA, Thomas SD (2000) Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen’s disease patients. J Biochem Mol Toxicol 14:140–147 doi:10.1002/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P

    Article  PubMed  CAS  Google Scholar 

  8. Ando Y, Fuse E, Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964–1973

    PubMed  CAS  Google Scholar 

Download references

Potential conflict of interest

Nothing to report.

Author information

Authors and Affiliations

  1. Department of Hematology–Oncology, CHUQ Research Center, Laval University, 11 côte du Palais, Hôtel-Dieu de Quebec, Quebec, Canada

    Eric Levesque

  2. Department of Gastroenterology, CHUQ Research Center, Laval University, 11 côte du Palais, Hôtel-Dieu de Quebec, Quebec, Canada

    Marc Bradette

Authors
  1. Eric Levesque
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Bradette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Levesque.

Additional information

E.L. is a holder of a CIHR clinician–scientist award.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levesque, E., Bradette, M. Hepatotoxicity as a rare but serious side effect of Thalidomide. Ann Hematol 88, 183–184 (2009). https://doi.org/10.1007/s00277-008-0559-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-008-0559-8

Keywords

Search

Navigation